Latest Asx Companies News

Sandon Capital Investments reports a robust 72% increase in net profits, driven by a 32.2% portfolio return that more than doubles market performance, alongside a healthy fully franked dividend yield.

Star Minerals Limited addresses a sharp rise in its share price and trading volume, attributing the movement to pending assay results from recent drilling activities. The company confirms compliance with ASX disclosure rules while preparing to release interpreted data.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

Miramar Resources has extended its Share Purchase Plan closing date to 27 August 2025, giving shareholders more time to invest at a 20% discount as the company awaits critical exploration results.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

RBR Group stands uniquely positioned as the only ASX-listed company directly linked to Mozambique’s LNG megaprojects, gearing up for a sector revival and broader African growth.

ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.

Pro Medicus Limited has renewed a significant five-year contract with Franciscan Missionaries of Our Lady Health System, marking a strategic shift to cloud-based medical imaging solutions and promising new revenue streams.

Orange Minerals NL has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information and confirming compliance with listing rules.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Vitasora Health has expanded its partnership with The Physician Alliance Corporation from a pilot to a multi-year value-based care contract covering up to 15,000 Medicare patients, unlocking significant new revenue streams tied to patient outcomes.